Autopsy report · NCT03601897

A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors

“Development program terminated.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 3 years 7 months before it stopped.
• 177 participants enrolled.
• Results were posted on the registry 2 years 7 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Deciphera Pharmaceuticals, LLC

Sponsor type

Industry

Conditions

Locally Advanced or Metastatic Solid Tumor

Interventions

Rebastinib; Paclitaxel

Participants

177

Sites

14

Countries

United States

Trials that died the same way

• GALLANT 22 Tesaglitazar vs. Placebo
  “The development program has been terminated” (94% match in meaning)
• Electroporation Therapy With Bleomycin in Treating Patients With Pancreatic Cancer
  “Program terminated” (80% match in meaning)
• A Randomized Double Blind, Placebo Controlled Trial With AMG 108 in Patients With Type 2 Diabetes Mellitus
  “Program Development discontinued” (70% match in meaning)
• Physician's Comfort Level and Satisfaction Study With The e2TM Collector Compared to the Spatula/CytoBrush Technique
  “Terminated for lack of resources to complete.” (67% match in meaning)
• Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
  “Program terminated due to lack of meaningful efficacy signal.” (65% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.